

Tomas Stopka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1070345/publications.pdf>

Version: 2024-02-01

75
papers

2,453
citations

257450

24
h-index

197818

49
g-index

75
all docs

75
docs citations

75
times ranked

4050
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. <i>Cells</i> , 2022, 11, 223.	4.1	5
2	Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization. <i>Cells</i> , 2022, 11, 808.	4.1	3
3	Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas. <i>Cancers</i> , 2022, 14, 2305.	3.7	2
4	Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6729.	4.1	3
5	G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	2
6	The chromatin remodeler Snf2h is essential for oocyte meiotic cell cycle progression. <i>Genes and Development</i> , 2020, 34, 166-178.	5.9	21
7	Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. <i>Molecular Oncology</i> , 2020, 14, 2403-2419.	4.6	7
8	Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2073.	4.1	19
9	ISWI ATPase Smarca5 Regulates Differentiation of Thymocytes Undergoing $\hat{\iota}^2$ -Selection. <i>Journal of Immunology</i> , 2019, 202, 3434-3446.	0.8	10
10	Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (<scp>MGUS</scp>): clinical findings in twelve patients including recurrence after keratoplasty. <i>Acta Ophthalmologica</i> , 2019, 97, e987-e992.	1.1	13
11	Lenalidomide treatment in lower risk myelodysplastic syndromes – The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in) <i>Tj ETQq1 1 0.784314 rgBT /@verlock</i>	1.4	10
12	BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2018, 103, 2016-2025.	3.5	30
13	Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacitidine (Data from Czech MDS) <i>Tj ETQq1 1 0.784314 rgBT /@verlock</i>	1.4	10
14	Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options. <i>Blood</i> , 2018, 132, 5506-5506.	1.4	1
15	Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System. <i>Blood</i> , 2018, 132, 3087-3087.	1.4	0
16	The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells. <i>Stem Cells</i> , 2017, 35, 1614-1623.	3.2	37
17	Prediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2116.	4.1	27
18	Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2136.	4.1	33

#	ARTICLE	IF	CITATIONS
19	Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders. <i>Oncotarget</i> , 2017, 8, 111966-111978.	1.8	8
20	Oncogenic microRNAs to predict relapse in early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23021-e23021.	1.6	0
21	GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia. <i>PLoS ONE</i> , 2016, 11, e0152234.	2.5	17
22	Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: Evidence for co-repressor functions. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 1515-1526.	1.9	8
23	Chromatin remodeling enzyme Snf2h regulates embryonic lens differentiation and denucleation. <i>Development (Cambridge)</i> , 2016, 143, 1937-1947.	2.5	41
24	Frequency and Clinical Impact of Cytogenetic Clonal Evolution in Myelodysplastic Syndromes (MDS) with Isolated Del(5q). <i>Blood</i> , 2016, 128, 1982-1982.	1.4	0
25	Graded PU.1 Levels Regulate Granulocyte Vs. Macrophage Genes Via Multiple Enhancer Elements. <i>Blood</i> , 2016, 128, 403-403.	1.4	0
26	Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome. <i>Blood</i> , 2016, 128, 4294-4294.	1.4	0
27	Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study. <i>Blood</i> , 2016, 128, 1767-1767.	1.4	0
28	Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. <i>International Journal of Hematology</i> , 2015, 102, 441-450.	1.6	17
29	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 887-899.	2.5	67
30	Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment. <i>Blood</i> , 2015, 126, 1243-1243.	1.4	0
31	Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness. <i>Blood</i> , 2015, 126, 4103-4103.	1.4	0
32	Azacitidine Blocks GATA-1-Mediated Repression of the PU.1 Gene in Human Leukemic Cells. <i>Blood</i> , 2015, 126, 5220-5220.	1.4	0
33	Snf2h-mediated chromatin organization and histone H1 dynamics govern cerebellar morphogenesis and neural maturation. <i>Nature Communications</i> , 2014, 5, 4181.	12.8	71
34	Transcriptional and Epigenetic Regulation in the Development of Myeloid Cells: Normal and Diseased Myelopoiesis. <i>Epigenetics and Human Health</i> , 2014, , 223-245.	0.2	0
35	Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. <i>BMC Cancer</i> , 2014, 14, 448.	2.6	149
36	Epigenetic Control of SPI1 Gene by CTCF and ISWI ATPase SMARCA5. <i>PLoS ONE</i> , 2014, 9, e87448.	2.5	25

#	ARTICLE	IF	CITATIONS
37	Role of Epigenetics in Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 28-36.	2.3	52
38	Mutation Of The Divalent Metal Transporter (Dmt1) Gene Results In Inefficient Induction Of The Erythroid Transcriptional Program Due To Latter Onset Of GATA-1 and Epor Expression. <i>Blood</i> , 2013, 122, 2197-2197.	1.4	0
39	Oncogenic Micrnas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma. <i>Blood</i> , 2013, 122, 1777-1777.	1.4	0
40	Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS. <i>Blood</i> , 2013, 122, 1558-1558.	1.4	0
41	Divalent Metal Transporter 1 (DMT1) Regulates EPO Receptor Gene Expression Via GATA-1. <i>Blood</i> , 2012, 120, 991-991.	1.4	0
42	MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 3816-3825.	1.4	128
43	Expression patterns of microRNAs associated with CML phases and their disease related targets. <i>Molecular Cancer</i> , 2011, 10, 41.	19.2	124
44	Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. <i>EMBO Journal</i> , 2011, 30, 4450-4464.	7.8	85
45	The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. <i>Leukemia</i> , 2010, 24, 1249-1257.	7.2	151
46	GATA-1 directly regulates p21 gene expression during erythroid differentiation. <i>Cell Cycle</i> , 2010, 9, 1972-1980.	2.6	36
47	The Oncogenic Mir-17-92 MicroRNA Cluster Is Inhibited by EGR2 During Macrophage Differentiation Via JARID1b-Mediated Histone 3 Lysine 4 Demethylation. <i>Blood</i> , 2010, 116, 390-390.	1.4	0
48	Smarca5 Regulates Ctf Recruitment to Chromatin, Including to Regulatory Loci Involved In Control of Globin Gene Expression In Erythroleukemia. <i>Blood</i> , 2010, 116, 5159-5159.	1.4	0
49	5-Azacytidine and G-CSF Derepressed Chromatin Structure of PU.1 and Its Targets Cebpa and Cbfb In Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2010, 116, 124-124.	1.4	0
50	ISWI Chromatin Remodeling ATPase Smarca5 (Snf2h) Is Required for Murine Erythroid Development and Globin Gene Regulation. <i>Blood</i> , 2010, 116, 2062-2062.	1.4	0
51	Active Chromatin Structure near MYB Occupancy at the Mir-155 Host Gene Promoter Coincides with Increased Mir-155 and MYB Levels In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3589-3589.	1.4	0
52	PU.1 Activation Relieves GATA-1-Mediated Repression of <i>Cebpa</i> and <i>Cbfb</i> during Leukemia Differentiation. <i>Molecular Cancer Research</i> , 2009, 7, 1693-1703.	3.4	22
53	MicroRNA Mir-155 and Myb Proto-Oncogene Family Members Cooperate in Pathogenesis of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 58-58.	1.4	3
54	Nuclear localization of ISWI ATPase Smarca5 Snf2h in mouse. <i>Frontiers in Bioscience - Elite</i> , 2009, E1, 553-559.	1.8	3

#	ARTICLE	IF	CITATIONS
55	Chromatin remodeling and SWI/SNF2 factors in human disease. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6126.	3.0	14
56	Gata1 Regulates Erythroid Transcription by Cooperating with Chromatin Remodeling Protein Snf2h. <i>Blood</i> , 2008, 112, 4759-4759.	1.4	0
57	Transcription Factors PU.1 and EGR2 Inhibits the Oncogenic Microrna Cluster Mir-17-92 during Macrophage Differentiation. <i>Blood</i> , 2008, 112, 473-473.	1.4	0
58	Disruption of a Functional Relationship Between PU.1 and Mir-155 during the Pathogenesis of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 3148-3148.	1.4	5
59	Modifiers of epigenetic reprogramming show paternal effects in the mouse. <i>Nature Genetics</i> , 2007, 39, 614-622.	21.4	154
60	Mutual Regulatory Loop between miR-155 and PU.1 Is a Candidate Pathogenesis Factor in CLL. <i>Blood</i> , 2007, 110, 1130-1130.	1.4	1
61	ISWI ATPase Snf2h Is Required for Both Heterochromatin and Euchromatin Structure in ES Cells. <i>Blood</i> , 2007, 110, 4062-4062.	1.4	0
62	Fog1 and Cebpa Are DNA Targets of GATA-1/PU.1 Antagonism during Leukemia Differentiation. <i>Blood</i> , 2007, 110, 4121-4121.	1.4	0
63	Regulation of α -crystallin via Pax6, c-Maf, CREB and a broad domain of lens-specific chromatin. <i>EMBO Journal</i> , 2006, 25, 2107-2118.	7.8	93
64	PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. <i>EMBO Journal</i> , 2005, 24, 3712-3723.	7.8	138
65	PU.1 and pRb Bind GATA-1 on DNA and Recruit a Histone H3K9 Methyl Transferase-Containing Complex to Repress the Erythroid Transcription Program. <i>Blood</i> , 2004, 104, 1614-1614.	1.4	0
66	Diamond blackfan anemia stem cells fail to repopulate erythropoiesis in NOD/SCID mice. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31, 93-97.	1.4	10
67	PU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid Differentiation. <i>Molecular and Cellular Biology</i> , 2003, 23, 7460-7474.	2.3	87
68	The ISWI ATPase Snf2h is required for early mouse development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 14097-14102.	7.1	178
69	TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. <i>Leukemia</i> , 2002, 16, 67-73.	7.2	108
70	Inhibition of Smad5 in Human Hematopoietic Progenitors Blocks Erythroid Differentiation Induced by BMP4. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 28, 221-233.	1.4	39
71	Ribosomal proteins S3a, S13, S16, and S24 are not mutated in patients with Diamond-Blackfan anemia. <i>Blood</i> , 2001, 97, 579-580.	1.4	8
72	Diagnosis of Polycythemia Vera in an Anemic Patient. <i>Southern Medical Journal</i> , 2000, 93, 710-712.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Ribosomal Protein S19 Gene Mutations in Patients with Diamond-Blackfan Anemia and Identification of Ribosomal Protein S19 Pseudogenes. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 124-132.	1.4	44
74	Two New EPO Receptor Mutations: Truncated EPO Receptors Are Most Frequently Associated With Primary Familial and Congenital Polycythemia. <i>Blood</i> , 1997, 90, 2057-2061.	1.4	116
75	Angiotensin II stimulates proliferation of normal early erythroid progenitors. <i>Journal of Clinical Investigation</i> , 1997, 100, 2310-2314.	8.2	231